Live Breaking News & Updates on Professor Gerhard Ehninger
Stay updated with breaking news from Professor gerhard ehninger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article DRESDEN, Germany, Feb. 3, 2021 /PRNewswire/ GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced interim data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the Virtual 3 rd EHA-EBMT European CAR-T-Cell Meeting, which is held from February 04-06, 2021. The data are being presented as oral presentation by Dr. Martin Wermke, University Hospital Dresden, Germany (February 05, 12:20 CET) and as a poster presentation by Dr. Sabrina Kraus, University Hospital Würzburg, Germany (Abstract 68). These clinical results present a promising step forward as we continue to evaluate the safety and efficacy of UniCAR-T-CD123, said Professor Gerhard Ehninger, Chief Medical Officer of GEMoaB. We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy ....
Share this article DRESDEN, Germany, Jan. 7, 2021 /PRNewswire/ GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to- treat cancers, today announced the acceptance of two presentations on clinical data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the 2021 EHA-EBMT 3rd European CAR T-Cell Meeting, being held from February 4-6. So far, CAR-T cell therapy in AML has been impacted by the lack of antigens differentially expressed on malignant blasts. Targeting CD123, which is also expressed on hematopoietic progenitor cells, with conventional CAR-T products has led to promising response rates but also to long-lasting aplasias, with the frequent need for subsequent allogeneic hematopoietic cell transplantation. ....